Efficacy Study in Removing Excess Iron From the Heart

This study has been completed.
Sponsor:
Information provided by:
ApoPharma
ClinicalTrials.gov Identifier:
NCT00105495
First received: March 15, 2005
Last updated: March 13, 2007
Last verified: October 2006
  Purpose

The purpose of this study is to determine whether deferiprone has superior efficacy in removing excess iron from the heart when compared with deferoxamine.


Condition Intervention Phase
Thalassemia Major
Hemosiderosis
Drug: Ferriprox (deferiprone)
Drug: Desferal (deferoxamine)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients

Resource links provided by NLM:


Further study details as provided by ApoPharma:

Primary Outcome Measures:
  • To determine whether deferiprone exhibits superior efficacy in removing excess iron from the heart compared to that of deferoxamine, as reflected by MRI T2* assessments in the heart in participants treated with either chelator

Secondary Outcome Measures:
  • To evaluate the relative efficacy of deferiprone with respect to that of deferoxamine as assessed by serum ferritin concentration and liver iron concentration (LIC)

Estimated Enrollment: 60
Study Start Date: December 2002
Estimated Study Completion Date: October 2004
Detailed Description:

This study is a multi-center, randomized, open-label, controlled clinical trial. The study population is participants with thalassemia major who are receiving regular chelation therapy with deferoxamine. A total of sixty (60) participants will be enrolled among the investigative sites.

The primary objective of this study is to determine whether deferiprone exhibits superior efficacy in removing excess iron from the heart compared to that of the standard therapy, deferoxamine.

The secondary objective is to evaluate the relative efficacy of deferiprone with respect to that of deferoxamine as assessed by serum ferritin concentration and liver iron concentration.

The primary efficacy measure in this study will be the participants' cardiac iron status, as determined by heart MRI T2* assessments.

The secondary efficacy measure will be by serum ferritin concentration and liver iron concentration. This will be measured by the Superconducting Quantum-Interference Device (SQUID) BioSusceptometer.

The duration of treatment is 12 months.

  Eligibility

Ages Eligible for Study:   18 Years to 36 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of thalassemia major as confirmed by laboratory and clinical criteria
  • Participants who are well transfused-maintaining a mean pre-transfusion Hb (hemoglobin) no less than 9 g/dL.
  • Between 18 and 36 years of age.
  • Receiving ongoing chelation therapy with deferoxamine for at least the past five years. Those who have been exposed to deferiprone for

    ≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.

  • Abnormal heart MRI T2* greater than or equal to 8 ms and < 20 ms.
  • If female, fertile, and is neither pregnant nor lactating, confirms she will use an effective method of contraception for the length of the trial and has a negative pregnancy test immediately prior to commencement of study drug OR has had a tubal ligation OR a hysterectomy OR is post menopausal (at least 1 year no menses prior to enrollment in the study) OR their only sexual partner has been sterilized (if male).
  • If male and fertile, he confirms that he and/or his partner will use an effective method of contraception for the length of the trial.
  • Provide a signed and witnessed written informed consent obtained prior to the first study intervention.

Exclusion Criteria:

  • Have anemia other than thalassemia.
  • HIV antibody positive.
  • Clinical evidence of cardiomyopathy as shown by LV Shortening Fraction < 30 % and/or CMR derived LV (left ventricular) Ejection Fraction < 56 %.
  • Severe/significant arrhythmia, including those who have had atrial fibrillation (participants with occasional ectopic beats and normal echo can be included) or those requiring treatment.
  • Previously discontinued therapy with deferiprone or deferoxamine because of an adverse drug reaction to either chelator.
  • Have received deferiprone in the last five years. However those who have been exposed to deferiprone for ≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.
  • Evidence of abnormal liver function (liver enzymes > 3 times upper limit of normal – entry may be delayed until return to normal).
  • Have disorders associated with neutropenia (ANC < 1.5 x 10^9/L) or thrombocytopenia (platelet count <50 x 10^9/L) in the twelve months prior to start of study medication, except for participants who have been treated with interferon and in whom the ANC has fully recovered. Participants with neutropenia or thrombocytopenia in the last year, which resolved with splenectomy, may be considered for this study.
  • Those who refuse to participate in the screening procedures or who are unable to participate in screening procedures or who are unable to comply with requirements of the protocol.
  • Receiving other investigational products.
  • Those in the opinion of the Investigator, who represent poor medical, psychological or psychiatric risks for whom participation in an investigational trial would be unwise.
  • Those who are pregnant, breastfeeding or planning to become pregnant during the study period.
  • Metallic objects in his/her body, such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas.
  • History of malignancy.
  • Participants with claustrophobia.
  • History of alcohol or drug abuse.
  • Participants who are, in the opinion of the Investigator, excessively obese.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00105495

Locations
Greece
Aghia Sophia Children's Hospital
Athens, Greece, 11527
1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital
Athens, Greece, 11527
Italy
Ospedale Regionale Microcitemie, Dipartimento di Scienze
Cagliari, Sardegna, Italy, 09100
Dipartimento di Scienze e Dell' Adolescenza, University of Turin
Turin, Italy, 10126
Sponsors and Collaborators
ApoPharma
Investigators
Principal Investigator: Renzo Galanello, M.D. Ospedale Regionale Microcitemie, Cagliari, Italy
Principal Investigator: Antonio Piga, M.D. Dipartimento di Scienze Pediatriche e Dell'Adolescenza, University of Turin, Turin, Italy
Principal Investigator: Markissia Karagiorga, M.D. Aghia Sophia Children's Hospital, Athens, Greece
Principal Investigator: Vassilis Ladis, M.D. 1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital, Athens, Greece
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00105495     History of Changes
Other Study ID Numbers: LA16-0102
Study First Received: March 15, 2005
Last Updated: March 13, 2007
Health Authority: European Union: European Medicines Agency

Keywords provided by ApoPharma:
Iron Overload
Thalassemia
Haemosiderosis
Cardiac
Deferiprone
Chelation

Additional relevant MeSH terms:
Beta-Thalassemia
Hemosiderosis
Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Deferoxamine
Deferiprone
Siderophores
Iron Chelating Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014